Klin Farmakol Farm. 2016;30(1):38-41 | DOI: 10.36290/far.2016.008

Stribild and its current position in HIV therapy

David Jilich

Klinika infekčních, tropických a parazitárních nemocí, Nemocnice Na Bulovce, Praha

Due to the wide use of antiretroviral therapy in the treatment of HIV infection there was a significant decrease in morbidity

and mortality of infected persons. This kind of treatment has significantly improved its effectiveness and safety, in the last

two decades. The main remaining limits of antiretroviral therapy are the toxicity and viral resistance. A key factor affecting the

emergence of viral resistance is drug adherence. The drug adherence puts relatively high demands onpatient’s self-discipline.

Fortunately, in the current period are available treatment options reflecting the need of comfort therapy schemes. Trend of

the last years are so-called fixed-dosed combinations, tablets containing more than one active substance. The top of this

strategy are single-tablet regimens (STR), integrating all active substances of patient’s antiretroviral therapy into one single

tablet, which is used once daily.

Keywords: HIV, Stribild, antiretroviral therapy, integrase inhibitors, single-tablet regimen

Published: May 30, 2016  Show citation